Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Female or male aged ≥4 years at the time of informed consent~2. Physician diagnosis of asthma with a documented history of the last 6 months~3. Receiving 1 of the following inhaled asthma medications with stable dosing for at least 30 days prior to Visit 1:~   * Only short/rapid-acting β2-adrenoreceptor agonist (SABA) used as needed~  * Stable low-dose inhaled corticosteroid in addition to as-needed use of SABA~4. Pre-bronchodilator FEV1 of ≥50 to \<85% predicted normal value for adults (≥18 years of age) and ≥50% predicted normal value for subjects aged 4 to 17 years after withholding SABA ≥6 hours at Visit 1.~5. Demonstrate reversibility of airflow limitation defined as a ≥15% increase in FEV1 relative to baseline after administration of Sponsor-provided SABA (Ventolin) at either Visit 1 or Visit 1a.~6. Demonstrate acceptable spirometry performance acceptability/repeatability criteria~7. Taken Ventolin on ≥2 days out of 7 days prior to Visit 2~8. Demonstrate acceptable metered dose inhaler (MDI) administration technique as assessed by the investigator.~9. Able to perform acceptable and reproducible peak expiratory flow measurements as assessed by the investigator~Exclusion Criteria:~1. Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)~2. Systemic corticosteroids (SCS) use (any dose and any indication) within 3 months before Visit 1~3. Chronic (≥3 weeks) use of SCS within 6 months prior to Visit 1~4. Received any marketed (eg, omalizumab, mepolizumab, reslizumab, benralizumab) or investigational biologic within 3 months or 5 half-lives before Visit 1, whichever is longer, or any other prohibited medication~5. Current smokers, former smokers with \>10 pack-years history, or former smokers who stopped smoking \<6 months before Visit 1 (including all forms of tobacco, e-cigarettes \[vaping\], and marijuana)~6. Life-threatening asthma defined as any history of significant asthma episode(s) requiring admission to an intensive care unit, intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s) within 5 years of Visit 1~7. Completed treatment for lower respiratory infection within 6 weeks prior to Visit 1~8. Upper respiratory infection involving antibiotic treatment not resolved within 7 days prior to Visit 1~9. Hospitalizations due to asthma within 6 months prior to Visit 1~10. Have taken ≥12 actuations per day of Sponsor-provided Ventolin during the run-in period prior to Visit 2 according to the below criteria:~    * ≥2 days out of 14 days of run-in~   * ≥3 days out of 15 to 21 days of run-in~   * ≥4 days out of 22 or more days of run-in~11. Unable to comply with study procedures including non-compliance with diary completion (ie, \<70% subject completion of diary assessments in the last 7 days preceding Visit 2 or 4-times daily dosing, \<80% compliance during the placebo run-in period).~12. Historical or current evidence of a clinically significant disease~13. Cancer not in complete remission for at least 5 years before Visit 1~14. Hospitalization for psychiatric disorder or attempted suicide within 1 year of Visit 1~15. History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting informed consent validity~16. Significant abuse of alcohol or drugs, in the opinion of the investigator

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BDA MDI (PT027) 160/180 μg (Type: EXPERIMENTAL): Budesonide/Albuterol sulfate BDA MDI (PT027) high dose
- BDA MDI (PT027) 80/180 μg (Type: EXPERIMENTAL): Budesonide/Albuterol sulfate BDA MDI (PT027) low dose
- BD MDI (PT008) 160 µg (Type: ACTIVE_COMPARATOR): Budesonide BD MDI (PT008)
- AS MDI (PT007) 180 µg (Type: ACTIVE_COMPARATOR): Albuterol sulfate AS MDI (PT007)
- Placebo MDI (Type: PLACEBO_COMPARATOR): Placebo MDI

Based on this trial design, predict the completion outcome and termination type (if applicable).